IDEAYA Biosciences

IDEAYA Biosciences

IDEAYA Biosciences was founded with a focus on precision medicine, targeting genetically defined cancers. The firm's approach centers on identifying tumor vulnerabilities and designing first-in-class therapies, with operations based in South San Francisco and an office in San Diego. Its wealth origin is not disclosed as a family office, and the company operates as a publicly traded biotech entity (per firm website). IDEAYA's R&D strategy spans several therapeutic areas: PKC inhibition in uveal melanoma, ADC+DDR combinations to improve TOP1 antibody-drug conjugates, MTAP pathway exploitation for metabolic vulnerabilities, and KAT6/7 inhibition targeting epigenetic drivers. The firm's lead program, darovasertib, is in late-stage trials for all stages of uveal melanoma, with a planned regulatory submission for metastatic disease by the second half of 2026 (per firm website). Geographic footprint remains North America-focused, with no disclosed international offices. As a publicly traded company, IDEAYA's financials are disclosed through SEC filings; however, no standalone AUM or deployment figures are available. The firm employs a discovery-to-delivery model, conducting early research and advancing candidates through clinical trials to regulatory approval. A noted recent event is the anticipated darovasertib submission for mUM in H2 2026, signaling a pivotal milestone for the firm. IDEAYA's structural differentiator is its focus on first-in-class targeted therapies for molecularly defined cancers, a niche that requires deep biological understanding and precise patient selection. This contrasts with broader oncology approaches, emphasizing therapeutic development lifecycle management and clinical-stage execution as its core operational model.